Investigational drug · Phase 3
Bevonescein
Also called: ALM-488
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Surgery, Nerve Injury, Imaging.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
5
Any phase or sponsor naming "Bevonescein"
First trial start
2022
Apr 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bevonescein", any sponsor or status.
Conditions studied
As listed on its trial records.
- Surgery
- Nerve Injury
- Imaging
- Head and Neck Surgery
Approved drugs for the same conditions: Head and neck cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "Bevonescein" as an intervention, largest first.
- Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck SurgeryPivotal-lookingCompleted
Alume Biosciences, Inc.Industry
NCT06227585 · 155 participants · Start Nov 29, 2023 · Primary completion Oct 24, 2025
Drug: Bevonescein · For: Head and Neck Surgery
Sites: La Jolla, California
- Bevonescein for Intra-Operative Nerve Visualization in Head and Neck SurgeryPivotal-lookingCompleted
Alume Biosciences, Inc.Industry
NCT05377554 · 154 participants · Start Apr 29, 2022 · Primary completion Oct 27, 2025
Drug: Bevonescein · For: Surgery
Sites: La Jolla, California
Matthew SpectorAcademic, hospital or other
NCT07631650 · 40 participants (planned) · Start Nov 4, 2026 · Primary completion Nov 4, 2027
Drug: Bevonescein (ALM 488) Infusion · For: Head and Neck Disorder; Head and Neck Cancer
Sites: Pittsburgh, Pennsylvania
Alume Biosciences, Inc.Industry
NCT04420689 · 27 participants · Start Jun 18, 2020 · Primary completion Jun 25, 2021
Drug: Bevonescein · For: Parotid Neoplasm; Thyroid Neoplasms; Head and Neck Neoplasms and 3 more
Sites: San Diego, California; Stanford, California; Boston, Massachusetts
Alume Biosciences, Inc.Industry
NCT06662097 · 27 participants · Start Oct 16, 2024 · Primary completion Jan 2, 2026
Drug: Bevonescein · For: Surgery; Nerve Injury; Imaging
Sites: San Diego, California
Newest research
PubMed records naming it or its code names, newest first.
- Nerve-targeted Fluorophores for Intraoperative Facial Nerve Visualization: A Scoping Review of Translational Readiness and Evidence Gaps.
Saad CG, Matar DY, Menendez JP, et al. · Plast Reconstr Surg Glob Open 2026
- Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer.
Eddins B, Kuo TC, Kwon H, et al. · Cancers (Basel) 2026
- Intraoperative Real-Time Fluorescence Labeling of Degenerated Facial Nerves with Bevonescein.
Crawford KL, Berman E, Whitney MA, et al. · Plast Reconstr Surg 2026
- Intraoperative nerve-specific fluorescence visualization in head and neck surgery: a Phase 1 trial.
Lee YJ, Orosco RK, Bouvet M, et al. · Nat Commun 2025
- Identification of Degenerated Murine Facial Nerves With Fluorescence Labeling After Transection Injury.
Crawford KL, Lee YJ, Hom M, et al. · Otolaryngol Head Neck Surg 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.